Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNG-DEPO vs Aranesp in Anemia of Chronic Kidney Disease on Dialysis
NCT05585645Phase 3Completed
- Sponsor
- Nanogen Pharmaceutical Biotechnology JSC
- Start
- Aug 2019
- Primary completion
- Nov 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of darbepoetin alfa in anemia (2 arms), sponsored by Nanogen Pharmaceutical Biotechnology JSC. Primary endpoint: Mean change in Hemoglobin level at 24 weeks. Started Aug 2019; status: completed.
02
Drugs
darbepoetin alfa
03
Conditions
anemia
Beyond the preview
Go deeper on NCT05585645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05585645.